Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$551 Mln
P/E Ratio
--
P/B Ratio
0.49
Industry P/E
--
Debt to Equity
0
ROE
-0.04 %
ROCE
-3.74 %
Div. Yield
0 %
Book Value
36.97
EPS
-1.39
CFO
$964.94 Mln
EBITDA
$540.57 Mln
Net Profit
$269.46 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Fulgent Genetics (FLGT)
| -2.71 | 6.39 | 5.09 | -11.74 | -32.97 | 3.35 | -- |
|
BSE Sensex
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Fulgent Genetics (FLGT)
| -35.88 | -2.92 | -70.39 | 93.07 | 303.88 | 306.94 | -27.50 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 133.44 | 11,202.40 | 13.05 | 159.08 | |
| 95.84 | 10,408.27 | 23.02 | 24.54 | |
| 110.51 | 11,495.49 | 3.72 | 110.75 | |
| 156.05 | 11,397.43 | 10.39 | 17.71 |
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic... testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California. Address: 4399 Santa Anita Avenue, El Monte, CA, United States, 91731 Read more
Chairman & CEO
Mr. Ming Hsieh
Chairman & CEO
Mr. Ming Hsieh
Headquarters
El Monte, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Fulgent Genetics Inc (FLGT) stood at $ 1,220 Mln as on 31-Dec-24
The share price of Fulgent Genetics Inc (FLGT) is $17.97 (NASDAQ) as of 21-Apr-2025 15:41 EDT. Fulgent Genetics Inc (FLGT) has given a return of -32.97% in the last 3 years.
Fulgent Genetics Inc (FLGT) has a market capitalisation of $ 551 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Fulgent Genetics Inc (FLGT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Fulgent Genetics Inc (FLGT) and enter the required number of quantities and click on buy to purchase the shares of Fulgent Genetics Inc (FLGT).
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California. Address: 4399 Santa Anita Avenue, El Monte, CA, United States, 91731
The CEO & director of Mr. Ming Hsieh. is Fulgent Genetics Inc (FLGT), and CFO & Sr. VP is Mr. Ming Hsieh.
There is no promoter pledging in Fulgent Genetics Inc (FLGT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,137
|
|
|
1,132
|
|
|
1,132
|
|
|
1,037
|
| Fulgent Genetics Inc. (FLGT) | Ratios |
|---|---|
|
Return on equity(%)
|
-3.76
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-15.07
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Fulgent Genetics Inc (FLGT) was $0 Mln.
$0.11
(
